SAN DIEGO, Dec. 7, 2015 /PRNewswire/ — BioAtla LLC, a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a license and option agreement with Pfizer Inc. (NYSE:PFE) to advance the development and commercialization of a new class of antibody …